49 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
. With our strengthened leadership team and balance sheet, we are ideally positioned to carry out our corporate strategy and, if approved, deliver a new
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
to identify a marketing partner for DCCR in Japan, and the rest of the world. The final decision on sales and marketing strategy will be made at a later … in a change in our regulatory strategy such as pursuing a narrower indication of use. If we are unable to adequately address any previous or further
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
for DCCR in Japan, and the rest of the world. The final decision on sales and marketing strategy will be made at a later date.
S-5
Pricing
We have … , or may result in a change in our regulatory strategy such as pursuing a narrower indication of use. If we are unable to adequately address any previous
8-K
0gax2ixlsdgbg 55
16 Aug 23
Departure of Directors or Certain Officers
9:00am
424B5
aas89abxpe9 8l5mu
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
y2vn540adi0gj2vw xlq
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
r21ib8
16 Jul 21
Prospectus supplement for primary offering
4:07pm
424B5
sarz5i j3k5qhbe
25 Jun 20
Prospectus supplement for primary offering
4:01pm